Heterogeneous expression of melanoma-associated antigens and HLA-A2 in metastatic melanoma in vivo

International Journal of Cancer

Volumn 75, Issue 4, 1998, Pages 517-524

  Cormier, Janice N ^a   Hijazi, Yasmine M ^a   Abati, Andrea ^a   Fetsch, Patricia ^a   Bettinotti, Maria ^b   Steinberg, Seth M ^a   Rosenberg, Steven A ^a   Marincola, Francesco M ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CLINICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN; HLA A2 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MELANOMA ANTIGEN; MONOCLONAL ANTIBODY HMB 45; TUMOR MARKER;

ADOPTIVE TRANSFER; ANTIGEN EXPRESSION; ANTIGEN RECOGNITION; ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; CYTOTOXIC LYMPHOCYTE; HLA TYPING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MELANOMA; METASTASIS; PRIORITY JOURNAL; TUMOR ASSOCIATED LEUKOCYTE;

ANTIGENS, NEOPLASM; HLA-A2 ANTIGEN; HUMANS; IMMUNOHISTOCHEMISTRY; MELANOMA; MEMBRANE GLYCOPROTEINS; NEOPLASM METASTASIS; NEOPLASM PROTEINS; PROSPECTIVE STUDIES; PROTEINS; TUMOR CELLS, CULTURED;

EID: 2642601105     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19980209)75:4<517::AID-IJC5>3.0.CO;2-W     Document Type: Article

References (22)

1. CORMIER, J.N., SALGALLER, M.L., PREVETTE, T., BARRACCHINI, K.C., RIVOLTINI, L., RESTIFO, N.P., ROSENBERG, S.A. and MARINCOLA, F.M., Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/MelanA. Cancer J. Sci. Amer., 3, 37-44 (1997).
2. COULIE, P.G., BRICHARD, V., VAN PEL, A., WÖLFEL, T., SCHNEIDER, J., TRAVERSARI, C., MATTEI, S., DE PLAEN, E., LURQUIN, C. and SZIKORA, J.P., A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas [see comments). J. exp. Med., 180, 35-42 (1994).
3. FERRONE, S. and MARINCOLA, F.M., Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol. Today, 16, 487-494 (1995).
4. FETSCH, P.A., FETSCH, J.F., MARINCOLA, F.M., TRAVIS, W., BATTS, K. and ABATI, A., Comparison of melanoma associated membrane antigen, MART-1, to HMB-45: further evidence to support a common lineage for angiolipoma (AML), lymphangiomyomatosis (LAM) and clear cell "sugar tumors" (CCST). Modern Pathol., 10, 42 (1997).
5. GARRIDO, F., CABRERA, T., LOPEZ-NEVOT, M.A. and RUIZ-CABELLO, F., HLA class I antigens in human tumors. Adv. Cancer Res., 67, 155-195 (1995).
6. HAHNE, M., RIMOLDI, D., SCHROTER, M., ROMERO, P., SCHREIER, M., FRENCH, L.E., SCHNEIDER, P., BORNAND, T., FONTANA, A., LIENARD, D., CEROTTINI, J.-C. and TSCHOPP, J., Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor immune escape. Science, 274, 1363-1366 (1996).
7. JÄGER, E., RINGHOFFER, M., DIENES, H.P., ARAND, M., KARBACH, J., JÄGER, D., ILSEMANN, C., HAGEDORN, M., OESCH, F. and KNUTH, A., Granulocytemacrophage colony-stimulating factor enhances immune responses to melanoma-associated peptides in vivo. Int. J. Cancer, 67, 54-62 (1996a).
8. JÄGER, E., RINGHOFFER, M., KARBACH, J., ARAND, M., OESCH, F. and KNUTH, A., Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CDS" cytotoxic T-cell responses: evidence for immunoselection of antigen-loss variants in vivo, Int. J. Cancer, 66, 470-476 (1996b).
9. KAWAKAMI, Y., BATTLES, J.K., KOBAYASHI, T., ENNIS, W., WANG, X., TUPESIS, J.P., MARINCOLA, P.M., ROBBINS, P.F., HEARING, V.J., GONDA, M.A. and ROSENBERG, S.A., Production of recombinant MART-1 proteins and specific antiMART-1 polyclonal and monoclonal antibodies: use in the characterization of the human melanoma antigen MART-1. J. immunol. Methods, 202, 13-25 (1997).
10. KAWAKAMI, Y., ELIYAHU, S., DELGADO, C.H., ROBBINS, P.F., RIVOLTINI, L., TOPALIAN, S.L., MIKI, T. and ROSENBERG, S.A., Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc. nat. Acad. Sci. (Wash.), 91, 3515-3519 (1994a).
11. KAWAKAMI, Y., ELIYAHU, S., DELGADO, C.H., ROBBINS, P.F., SAKAGUCHI, K., APPELLA, E., YANNELLI, J.R., ADEMA, G.J., MIKI, T. and ROSENBERG, S.A., Identification of a human melanoma antigen recognized by tumorinfiltrating lymphocytes associated with in vivo tumor rejection. Proc. nat. Acad. Sci. (Wash.), 91, 6458-6462 (1994b).
12. MAEURER, M.J., GOLLIN, S.M., MARTIN, D., SWANEY, W., BRYANT, J., CASTELLI, C., ROBBINS, P., PARMIANI, G., STORKUS, W.J. and LOTZE, M.T., Tumor escape from immune recognition: lethal recurrent melanoma in a patient associated with downregulation of the peptide transporter protein TAP-1 and loss of expression of the immunodominant MART-1/Melan-A antigen. J. clin. Invent., 98, 1633-1641 (1996).
13. MARINCOLA, F.M., HIJAZI, Y.M., FETSCH, P., SALGALLER, M.L., RIVOLTINI, L., CORMIER, J., SIMONIS, T.B., DURAY, P.H., HERLYN, M., KAWAKAMI, Y. and ROSENRERG, S.A., Analysis of expression of the melanoma associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in in situ lesions. J. Immunother., 19, 192-205 (1996).
14. PLAYER, M.A., BARRACCHINI, K.C., SIMONIS, T.B., RIVOLTINI, L., ARJENTI, F., CASTELLI, C., MAZZOCCHI, A., BELLI, F. and MARINCOLA, F.M., Differences in frequency distribution of HLA-A2 sub-types between American and Italian Caucasian melanoma patients: relevance for epitope specific vaccination protocols. J. Immunother., 19, 357-363 (1996).
15. 111indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response. Cancer, 73, 1731-1737 (1994).
16. RABINOWICH, H., BANKS, M., REICHERT, T.E., LOGAN, T.F., KIRKWOOD, J.M. and WHITESIDE, T.L., Expression and activity of signaling molecules in T lymphocytes obtained from patients with metastatic melanoma before and after interleukin-2 therapy. Clin. Cancer Res., 2, 1263-1274 (1996).
17. 2- 7 microglobulin in metastatic melanomas from five patients undergoing immunotherapy. J. nat. Cancer Inst., 88, 100-108 (1996).
18. RIVOLTINI, L., BARACCHINI, K.C., VIGGIANO, V., KAWAKAMI, Y., SMITH, A., MIXON, A., RESTIFO, N.P., TOPALIAN, S.L., SIMONIS, T.B., ROSENBERG, S.A. and MARINCOLA, F.M., Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen specific cytotoxic T lymphocytes. Cancer Res., 55, 3149-3157 (1995).
19. ROSENBERG, S.A., Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol. Today, 18, 175-182 (1997).
20. SALGALLER, M.L., MARINCOLA, F.M., CORMIER, J.N, and ROSENBERG, S.A., Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res., 56, 4749-4757 (1996).
21. SCHEIBENBOGEN, C., WEYERS, I., RUITER, D., WILLHAUCK, M., BITTINGER, A. and KEILHOLZ, U., Expression of gp100 in melanoma metastases resected before or after treatment with IFN alpha and IL-2. J. Immunother., 19, 375-380 (1996).
22. SLAWOMIR-PRAGA, S., Reversal of tumor-induced immunosuppression. A new approach to cancer therapy. J. Immunother., 20, 165-177 (1997).